Skip to content
To see all protocols that comply with the WHO Essential Medicine List
Cancer Institute NSW sites
eviQ Education
Learning resources for cancer staff
Cancer Institute NSW
NSW cancer control agency
Patient Information
Practical advice about cancer
Canrefer
Find a cancer specialist
BreastScreen NSW
Detect breast cancer early
Cervical Screening NSW
Cervical Screening NSW
iCanQuit
Learn how to quit smoking
Log in
Register
Search
Search
Log in
Register
Search
Main menu Toggle menu collaspe
Search eviQ
Close
Search
Search
Home
Home
Cancer genetics
Adult
Genetic testing for heritable pathogenic variants
Genetic testing using cancer gene panels
Risk management
Paediatric
Genetic testing for heritable pathogenic variants
Genetic testing using cancer gene panels
Risk management
Referral guidelines
Consumer information
Resources
Haematology and BMT
Leukaemias
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Acute promyelocytic leukaemia
Chronic lymphocytic leukaemia
Chronic myeloid leukaemia
Hairy cell leukaemia
Myelodysplastic disorders
Lymphoma
Non-Hodgkin lymphoma
Hodgkin lymphoma
Burkitt lymphoma
Mantle cell lymphoma
Primary CNS lymphoma
Waldenstrom macroglobulinaemia
Multiple myeloma
Blood and marrow transplant
Mobilisation
Allogeneic
Autologous
Cellular therapies
Medical oncology
Breast
Adjuvant/neoadjuvant
Metastatic
Colorectal
Adjuvant and neoadjuvant
Metastatic
Anal
Rectal
Gynaecological
Cervical
Endometrial
Gestational trophoblastic disease
Ovarian
Vulval
Head and neck
Definitive chemoradiation
Induction chemotherapy
Nasopharyngeal
Post operative chemoradiation
Recurrent or metastatic
Salivary gland
Thyroid
Neurological
Glioma
Respiratory
Mesothelioma
Non small cell lung cancer - Adjuvant/neoadjuvant
Non small cell lung cancer - Advanced/metastatic
Small cell lung cancer
Sarcoma
Soft tissue sarcoma
Bone sarcoma
Skin
Melanoma adjuvant
Melanoma metastatic
Non-melanoma
Upper gastrointestinal
Gastric and oesophageal adjuvant and neoadjuvant
Gastric and oesophageal metastatic
Gastrointestinal stromal cell tumours
Hepatic
Neuroendocrine
Pancreas and biliary
Urogenital
Adrenocortical
Bladder and Urothelial
Prostate
Renal
Testicular
Rare cancers
Colorectal
Gynaecological
Head and neck
Melanoma
Neurological
Respiratory
Sarcoma
Upper gastrointestinal
Urogenital
Radiation oncology
Breast
Colorectal
Gynaecological
Haematology
Head and neck
Neurological
Palliative
Respiratory
Upper gastrointestinal
Urogenital
Bladder
Prostate
Skin
Stereotactic
Clinical resources
eviQ calculators
Aboriginal health workers
ADDIKD guideline
Administration of anti-cancer drugs
Assessment tools
BMT & cellular therapies
Central venous access devices (CVADs)
Day of Treatment Assessment
Extravasation
Pumps
Health professional fact sheets
Oncological emergencies
Radiation oncology
Assessment tools
Cardiac implantable electronic devices
Contrast administration
Health professional fact sheets
Radiation-induced dermatitis
Side effect and toxicity management
Side effect and toxicity management
Cardiovascular
Gastrointestinal
General
Genitourinary
Gynaecological
Haematological
Hair, skin and nails
Immunological
Neurological and sensory
Oropharyngeal
Prophylaxis and treatment
Reproductive
Respiratory
Telephone triage toolkit
COVID-19
Patients and carers
Anticancer drug treatments
Radiation therapy treatments
Cancer genetics information sheets
Patient information sheets
At home
Cancer type specifics
Complementary and alternative medicines
Eating and drinking
Fertility, sex, pregnancy and breastfeeding
Treating cancer with medicines
How you have anticancer medicine treatment
Treating cancer with radiation therapy
How you have radiation therapy treatment
Managing side effects
Vaccinations
Your family and friends
Patient information in other languages
عربى (Arabic)
简 (Simplified Chinese)
繁 (Traditional Chinese)
Français (French)
Ελληνικά (Greek)
Italiano (Italian)
한국어 (Korean)
Español (Spanish)
Tiếng Việt (Vietnamese)
Македонски (Macedonian)
ไทย (Thai)
Patient information videos
Cancer Institute NSW sites
eviQ Education
Learning resources for cancer staff
Cancer Institute NSW
NSW cancer control agency
Patient Information
Practical advice about cancer
Canrefer
Find a cancer specialist
BreastScreen NSW
Detect breast cancer early
Cervical Screening NSW
Cervical Screening NSW
iCanQuit
Learn how to quit smoking
Home
1020 results for 'patient information'
Search
Protocols (0)
Clinical Resources (4)
Patients and Carers (1016)
No results found.
No results found.
No results found.
Clinical resources > Health professional fact sheets
Information to assist GPs in supporting patients receiving anticancer immunotherapy
Information to assist GPs in supporting patients receiving intravenous chemotherapy
Information to assist GPs in supporting patients receiving molecular targeted anticancer therapy
Information to assist GPs in supporting patients receiving oral chemotherapy
No results found.
Haematology and BMT > Blood and marrow transplant > Allogeneic
Patient information - Allogeneic conditioning - Busulfan and cyclophosphamide
Patient information - Allogeneic conditioning - Busulfan and fludarabine (Haploidentical)
Patient information - Allogeneic conditioning - Cyclophosphamide and ATGAM
Patient information - Allogeneic conditioning - Cyclophosphamide and busulfan (reversed order)
Patient information - Allogeneic conditioning - Cyclophosphamide and total body irradiation (TBI)
Patient information - Allogeneic conditioning - Cyclophosphamide, fludarabine and ATGAM
Patient information - Allogeneic conditioning - Cyclophosphamide, fludarabine and Thymoglobuline®
Patient information - Allogeneic conditioning - Cyclophosphamide, fludarabine, thiotepa and total body irradiation (TBI) (MIDI protocol)
Patient information - Allogeneic conditioning - Etoposide and total body irradiation (TBI)
Patient information - Allogeneic conditioning - FluBu2 (fludarabine and busulfan)
Patient information - Allogeneic conditioning - FluBu4 (fludarabine and busulfan)
Patient information - Allogeneic conditioning - Fludarabine and cyclophosphamide
Patient information - Allogeneic conditioning - Fludarabine and melphalan
Patient information - Allogeneic conditioning - Fludarabine and total body irradiation (TBI)
Patient information - Allogeneic conditioning - Fludarabine and total body irradiation (TBI)
Patient information - Allogeneic conditioning - Fludarabine, cyclophosphamide and alemtuzumab
Patient information - Cyclophosphamide, fludarabine and total body irradiation (TBI) (Haploidentical)
Patient information - Cyclophosphamide, fludarabine and total body irradiation (TBI) (reduced intensity)
Patient information - FLAMSA (fludarabine, cytarabine, amsacrine, cyclophosphamide and total body irradiation (TBI)) (MUD)
Patient information - FLAMSA (fludarabine, cytarabine, amsacrine, cyclophosphamide and total body irradiation (TBI)) (sibling)
Patient information - Fludarabine, carmustine and melphalan
Haematology and BMT > Blood and marrow transplant > Autologous
Patient information - Autologous conditioning - BEAM (carmustine, etoposide, cytarabine and melphalan)
Patient information - Autologous conditioning - Busulfan and melphalan
Patient information - Autologous conditioning - Carmustine and thiotepa
Patient information - Autologous conditioning - CBV (cyclophosphamide, carmustine and etoposide)
Patient information - Autologous conditioning - High dose melphalan 140 mg/m
2
Patient information - Autologous conditioning - High dose melphalan 200 mg/m
2
Patient information - Autologous conditioning - LACE (lomustine, cytarabine, cyclophosphamide and etoposide)
Haematology and BMT > Blood and marrow transplant > Mobilisation
Patient information - Mobilisation - Cyclophosphamide
Patient information - Mobilisation - Plerixafor and G-CSF
Haematology and BMT > Cellular therapies
Patient information - Acute lymphoblastic leukaemia (ALL) - Fludarabine, cyclophosphamide and tisagenlecleucel
Patient information - Diffuse large B-cell lymphoma - Fludarabine, cyclophosphamide and tisagenlecleucel
Patient information - Large B-cell lymphoma - Fludarabine, cyclophosphamide and axicabtagene ciloleucel
Haematology and BMT > Leukaemias > Acute lymphoblastic leukaemia
Patient information - Acute lymphoblastic leukaemia (ALL) - Blinatumomab
Patient information - Acute lymphoblastic leukaemia (ALL) - Dasatinib
Patient information - Acute lymphoblastic leukaemia (ALL) - Inotuzumab ozogamicin
Patient information - Acute lymphoblastic leukaemia (ALL) - MRD-positive blinatumomab
Patient information - Acute lymphoblastic leukaemia (ALL) - Ponatinib
Haematology and BMT > Leukaemias > Acute myeloid leukaemia
Patient information - Acute myeloid leukaemia (AML) - Azacitidine
Patient information - Acute myeloid leukaemia (AML) - Azacitidine
Patient information - Acute myeloid leukaemia (AML) - Azacitidine and venetoclax
Patient information - Acute myeloid leukaemia (AML) - Consolidation 5-2 Ida (cytarabine, idarubicin)
Patient information - Acute myeloid leukaemia (AML) - Consolidation cytarabine (age 60 years and over)
Patient information - Acute myeloid leukaemia (AML) - Consolidation cytarabine (age under 60 years)
Patient information - Acute myeloid leukaemia (AML) - FLAG (fludarabine, cytarabine, filgrastim)
Patient information - Acute myeloid leukaemia (AML) - FLAG-Ida (fludarabine, cytarabine, idarubicin, filgrastim)
Patient information - Acute myeloid leukaemia (AML) - Gilteritinib
Patient information - Acute myeloid leukaemia (AML) - Induction 7-3 (cytarabine and daunorubicin)
Patient information - Acute myeloid leukaemia (AML) - Induction 7-3 Ida (cytarabine, idarubicin)
Patient information - Acute myeloid leukaemia (AML) - Low dose cytarabine
Patient information - Acute myeloid leukaemia (AML) - Low dose cytarabine and venetoclax
Patient information - Acute myeloid leukaemia (AML) - Consolidation 5-2 (cytarabine, daunorubicin)
Patient information - Acute myeloid leukaemia (AML) - Consolidation HiDAC (cytarabine) 1,2,3
Patient information - Acute myeloid leukaemia (AML) - Consolidation HiDAC (cytarabine) 1,3,5
Patient information - Acute myeloid leukaemia (AML) - Consolidation IDAC (cytarabine)
Patient information - Acute myeloid leukaemia (AML) - Consolidation Little IcE 5 days (idarubicin, cytarabine, etoposide)
Patient information - Acute myeloid leukaemia (AML) - HAM (cytarabine, mitozantrone)
Patient information - Acute myeloid leukaemia (AML) - Induction 7-3 high dose daunorubicin (cytarabine, daunorubicin)
Patient information - Acute myeloid leukaemia (AML) - Induction 7-3-7 modified (cytarabine, idarubicin, etoposide)
Patient information - Acute myeloid leukaemia (AML) - Induction big ICE 7 Days (idarubicin, cytarabine, etoposide)
Patient information - Induction/consolidation (Lowenberg)
Haematology and BMT > Leukaemias > Acute promyelocytic leukaemia
Patient information - Arsenic trioxide induction
Patient information - Arsenic trioxide consolidation
Haematology and BMT > Leukaemias > Chronic lymphocytic leukaemia
Patient information - Acalabrutinib
Patient information - Chronic lymphocytic leukaemia (CLL) - Bendamustine and rituximab
Patient information - Chronic lymphocytic leukaemia (CLL) - Chlorambucil and obinutuzumab
Patient information - Chronic lymphocytic leukaemia (CLL) - FCR (fludarabine, cyclophosphamide, rituximab)
Patient information - Chronic lymphocytic leukaemia (CLL) - Ibrutinib
Patient information - Chronic lymphocytic leukaemia (CLL) - Idelalisib and rituximab
Patient information - Chronic lymphocytic leukaemia (CLL) - Venetoclax and obinutuzumab
Patient information - Chronic lymphocytic leukaemia (CLL) - Venetoclax and rituximab
Patient information - Chronic lymphocytic leukaemia (CLL) - Zanubrutinib
Patient information - Chronic lymphocytic leukaemia (CLL) - Chlorambucil
Haematology and BMT > Leukaemias > Chronic myeloid leukaemia
Patient information - Chronic myeloid leukaemia (CML) - Asciminib
Patient information - Chronic myeloid leukaemia (CML) - Dasatinib
Patient information - Chronic myeloid leukaemia (CML) - Imatinib
Patient information - Chronic myeloid leukaemia (CML) - Nilotinib
Patient information - Chronic myeloid leukaemia (CML) - Ph+ T315I mutation - Asciminib
Patient information - Chronic myeloid leukaemia (CML) - Ponatinib
Haematology and BMT > Leukaemias > Hairy cell leukaemia
Patient information - Hairy cell leukaemia - Cladribine
Patient information - Hairy cell leukaemia - Rituximab and cladribine
Haematology and BMT > Leukaemias > Myelodysplastic disorders
Patient information - Myelodysplastic syndrome - Azacitidine
Patient information - Myelodysplastic syndrome - Lenalidomide
Patient information - Primary myelofibrosis - Ruxolitinib
Haematology and BMT > Lymphoma
Patient information - Lymphoma - Bendamustine and rituximab
Patient information - Lymphoma - Brentuximab vedotin
Patient information - Lymphoma - DHAP (dexamethasone, cytarabine, cisplatin)
Patient information - Lymphoma - GDP (gemcitabine, dexamethasone, cisplatin)
Patient information - Lymphoma - Gemcitabine and vinorelbine
Patient information - Zanubrutinib
Patient information - Lymphoma - GIVE (G-CSF, ifosfamide, etoposide, epirubicin)
Haematology and BMT > Lymphoma > Burkitt lymphoma
Patient information - Burkitt lymphoma - DA-R-EPOCH (dose adjusted rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin)
Haematology and BMT > Lymphoma > Hodgkin lymphoma
Patient information - Hodgkin lymphoma - ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) advanced stage
Patient information - Hodgkin lymphoma - ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) early stage
Patient information - Hodgkin lymphoma - BEACOPP escalated dose (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procabazine, prednisolone)
Patient information - Hodgkin lymphoma - Brentuximab vedotin
Patient information - Hodgkin lymphoma - BV-ICE (brentuximab vedotin iFOSFamide cARBOplatin etoposide)
Patient information - Hodgkin lymphoma - ChlVPP (chlorambucil, vinblastine, procarbazine, prednisolone)
Patient information - Hodgkin lymphoma - DHAP (dexamethasone, cytarabine, cisplatin)
Patient information - Hodgkin lymphoma - GDP (gemcitabine, dexamethasone, cisplatin)
Patient information - Hodgkin lymphoma - Gemcitabine and vinorelbine
Patient information - Hodgkin lymphoma - ICE (fractionated ifosfamide, carboplatin, etoposide)
Patient information - Hodgkin lymphoma - IGEV (iFOSFamide gemcitabine vinORELBine prednisolone)
Patient information - Hodgkin lymphoma - Pembrolizumab
Patient information - Hodgkin lymphoma - PVAG (prednisolone, vinblastine, doxorubicin, gemcitabine)
Patient information - Hodgkin lymphoma - GIVE (G-CSF, ifosfamide, etoposide, epirubicin)
Patient information - Hodgkin lymphoma - ICE (infusional ifosfamide, carboplatin, etoposide)
Haematology and BMT > Lymphoma > Mantle cell lymphoma
Patient information - Acalabrutinib
Patient information - Mantle cell lymphoma - Ibrutinib
Patient information - Mantle cell lymphoma - R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone)
Patient information - Mantle cell lymphoma - R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin)
Patient information - Mantle cell lymphoma - Rituximab, bendamustine and cytarabine
Patient information - Mantle cell lymphoma - Zanubrutinib
Haematology and BMT > Lymphoma > Non-Hodgkin lymphoma
Patient information - Cutaneous T-Cell Lymphoma (CTCL) - Vorinostat
Patient information - Lymphoma - Pembrolizumab
Patient information - Natural killer/T-Cell lymphoma - DDGP (dexamethasone, cisplatin, gemcitabine, pegaspargase)
Patient information - Natural killer/T-Cell lymphoma - Modified SMILE (dexamethasone, methotrexate, ifosfamide, pegaspargase, etoposide)
Patient information - Natural killer/T-Cell lymphoma - SMILE (dexamethasone, methotrexate, ifosfamide, asparaginase, etoposide)
Patient information - Non-Hodgkin lymphoma - O-CVP (obinuzutumab, cyclophosphamide, vincristine, prednisolone)
Patient information - Non-Hodgkin lymphoma (NHL) - Bendamustine and obinutuzumab
Patient information - Non-Hodgkin lymphoma (NHL) - Bendamustine and rituximab
Patient information - Non-Hodgkin lymphoma (NHL) - Bendamustine polatuzumab vedotin and rituximab
Patient information - Non-Hodgkin lymphoma (NHL) - Brentuximab vedotin
Patient information - Non-Hodgkin lymphoma (NHL) - Chlorambucil and rituximab
Patient information - Non-Hodgkin lymphoma (NHL) - CHOEP14 (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone)
Patient information - Non-Hodgkin lymphoma (NHL) - CHOEP21 (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone)
Patient information - Non-Hodgkin lymphoma (NHL) - CHOP14 (cyclophosphamide, doxorubicin, vincristine, prednisolone)
Patient information - Non-Hodgkin lymphoma (NHL) - CHOP21 (cyclophosphamide, doxorubicin, vincristine, prednisolone)
Patient information - Non-Hodgkin lymphoma (NHL) - DA-R-EPOCH (dose adjusted rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin)
Patient information - Non-Hodgkin lymphoma (NHL) - DHAC (dexamethasone, cytarabine, carboplatin)
Patient information - Non-Hodgkin lymphoma (NHL) - DHAP (dexamethasone, cytarabine, cisplatin)
Patient information - Non-Hodgkin lymphoma (NHL) - ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin)
Patient information - Non-Hodgkin lymphoma (NHL) - GDP (gemcitabine, dexamethasone, cisplatin)
Patient information - Non-Hodgkin lymphoma (NHL) - Gemcitabine and vinorelbine
Patient information - Non-Hodgkin lymphoma (NHL) - ICE (fractionated ifosfamide, carboplatin, etoposide)
Patient information - Non-Hodgkin lymphoma (NHL) - ICE (infusional ifosfamide, carboplatin, etoposide)
Patient information - Non-Hodgkin lymphoma (NHL) - Idelalisib
Patient information - Non-Hodgkin lymphoma (NHL) - Obinutuzumab maintenance
Patient information - Non-Hodgkin lymphoma (NHL) - O-CHOP21 (obinutuzumab, cyclophosphamide, doxorubicin, vincristine, prednisolone)
Patient information - Non-Hodgkin lymphoma (NHL) - R-CHOEP14 (rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone)
Patient information - Non-Hodgkin lymphoma (NHL) - R-CHOP14 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone)
Patient information - Non-Hodgkin lymphoma (NHL) - R-CHOP21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone)
Patient information - Non-Hodgkin lymphoma (NHL) - R-CVP (rituximab, cyclophosphamide, vincristine, prednisolone)
Patient information - Non-Hodgkin lymphoma (NHL) - R-DHAOx (rituximab, dexamethasone, cytarabine, oxaliplatin)
Patient information - Non-Hodgkin lymphoma (NHL) - R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin)
Patient information - Non-Hodgkin lymphoma (NHL) - R-GDP (rituximab, gemcitabine, dexamethasone, cisplatin)
Patient information - Non-Hodgkin lymphoma (NHL) - R-GemOx (rituximab, gemcitabine, oxaliplatin)
Patient information - Non-Hodgkin lymphoma (NHL) - RICE (rituximab, fractionated ifosfamide, carboplatin, etoposide)
Patient information - Non-Hodgkin lymphoma (NHL) - RICE (rituximab, infusional ifosfamide, carboplatin, etoposide)
Patient information - Non-Hodgkin lymphoma (NHL) - Rituximab
Patient information - Non-Hodgkin lymphoma (NHL) - Rituximab maintenance
Patient information - Non-Hodgkin lymphoma (NHL) - R-MiniCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone)
Patient information - Non-Hodgkin lymphoma (NHL) - SMARTE-R-CHOP14 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone)
Patient information - Peripheral T-Cell lymphoma (PTCL) - BV-CHP (brentuximab vedotin, cyclophosphamide, doxorubicin and prednisolone)
Patient information - Peripheral T-Cell lymphoma (PTCL) - Pralatrexate
Patient information - Peripheral T-cell lymphoma romidepsin
Patient information - Non-Hodgkin lymphoma (NHL) - GIVE (G-CSF, ifosfamide, etoposide, epirubicin)
Patient information - Non-Hodgkin lymphoma (NHL) - Rituximab maintenance subcutaneous
Haematology and BMT > Lymphoma > Primary CNS lymphoma
Patient information - Primary CNS lymphoma - MATRix (methotrexate, cytarabine, thiotepa, rituximab)
Patient information - Primary CNS lymphoma - High dose methotrexate
Patient information - Primary CNS lymphoma - MBVP (methotrexate, carmustine, teniposide, prednisolone)
Patient information - Primary CNS lymphoma - Methotrexate and cytarabine
Haematology and BMT > Lymphoma > Waldenstrom macroglobulinaemia
Patient information - Waldenstrom macroglobulinaemia - DRC (dexamethasone, rituximab, cyclophosphamide)
Patient information - Waldenstrom macroglobulinaemia - Zanubrutinib
Haematology and BMT > Multiple myeloma
Patient information - AL amyloidosis - Daratumumab and CyBorD (cyclophosphamide, bortezomib and dexamethasone) weekly
Patient information - Multiple myeloma - CyBorD (cyclophosphamide, bortezomib and dexamethasone)
Patient information - Multiple myeloma - CyBorD (cyclophosphamide, bortezomib and dexamethasone) weekly
Patient information - Multiple myeloma - Daratumumab subcutaneous
Patient information - Multiple myeloma - Denosumab
Patient information - Multiple myeloma - DRd (daratumumab subcutaneous lenalidomide dexamethasone)
Patient information - Multiple myeloma - DT-PACE (dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide)
Patient information - Multiple myeloma - ERd (Elotuzumab, lenalidomide and dexamethasone)
Patient information - Multiple myeloma - Ixazomib lenalidomide and dexamethasone
Patient information - Multiple myeloma - KCd (carfilzomib, cyclophosphamide and dexamethasone)
Patient information - Multiple myeloma - Kd (carfilzomib and dexamethasone) twice weekly
Patient information - Multiple myeloma - Kd (carfilzomib and dexamethasone) weekly
Patient information - Multiple myeloma - KRd (carfilzomib lenalidomide dexamethasone)
Patient information - Multiple myeloma - Lenalidomide and dexamethasone
Patient information - Multiple myeloma - Lenalidomide maintenance
Patient information - Multiple myeloma - MPB (melphalan, prednisolone, bortezomib)
Patient information - Multiple myeloma - Pamidronate
Patient information - Multiple myeloma - PCAB (prednisolone, cyclophosphamide, doxorubicin, carmustine)
Patient information - Multiple myeloma - Pomalidomide and dexamethasone
Patient information - Multiple myeloma - Pomalidomide, cyclophosphamide and dexamethasone
Patient information - Multiple myeloma - PVd (pomalidomide bortezomib and dexamethasone)
Patient information - Multiple myeloma - Sd (selinexor and dexamethasone)
Patient information - Multiple myeloma - SVd (selinexor bortezomib and dexamethasone)
Patient information - Multiple myeloma - Zoledronic acid
Patient information - AL amyloidosis - Melphalan and dexamethasone
Patient information - Daratumumab
Patient information - Multiple myeloma - Bortezomib and dexamethasone (relapsed)
Patient information - Multiple myeloma - DRd (daratumumab lenalidomide dexamethasone)
Patient information - Multiple myeloma - PAD (bortezomib, doxorubicin, dexamethasone)
Patient information - Multiple myeloma - Thalidomide and dexamethasone
Patient information - Multiple myeloma and AL amyloidosis - CTD (cyclophosphamide, thalidomide, dexamethasone)
Medical oncology > Breast
Patient information - Breast cancer - Trastuzumab subcutaneous
Medical oncology > Breast > Adjuvant/neoadjuvant
Patient information - Breast cancer adjuvant - Abemaciclib
Patient information - Breast cancer adjuvant - Anastrozole
Patient information - Breast cancer adjuvant - Capecitabine (post neoadjuvant)
Patient information - Breast cancer adjuvant - Capecitabine metronomic
Patient information - Breast cancer adjuvant - CMF (cyclophosphamide, methotrexate, fluorouracil)
Patient information - Breast cancer adjuvant - EC (epirubicin and cyclophosphamide)
Patient information - Breast cancer adjuvant - Exemestane
Patient information - Breast cancer adjuvant - Exemestane and goserelin
Patient information - Breast cancer adjuvant - Goserelin
Patient information - Breast cancer adjuvant - Letrozole
Patient information - Breast cancer adjuvant - Paclitaxel dose dense
Patient information - Breast cancer adjuvant - Paclitaxel weekly and trastuzumab three weekly
Patient information - Breast cancer adjuvant - Tamoxifen
Patient information - Breast cancer adjuvant - TC (docetaxel and cyclophosphamide)
Patient information - Breast cancer adjuvant - TCH (docetaxel, carboplatin, trastuzumab)
Patient information - Breast cancer adjuvant - TH (docetaxel and trastuzumab) three weekly
Patient information - Breast cancer adjuvant - Trastuzumab emtansine
Patient information - Breast cancer adjuvant - Trastuzumab subcutaneous
Patient information - Breast cancer adjuvant/neoadjuvant - AC (doxorubicin and cyclophosphamide) dose dense
Patient information - Breast cancer adjuvant/neoadjuvant - AC (doxorubicin and cyclophosphamide) three weekly
Patient information - Breast cancer adjuvant/neoadjuvant - Docetaxel
Patient information - Breast cancer adjuvant/neoadjuvant - Paclitaxel weekly
Patient information - Breast cancer adjuvant/neoadjuvant - TAC (docetaxel, doxorubicin, cyclophosphamide)
Patient information - Breast cancer adjuvant/neoadjuvant - Trastuzumab three weekly
Patient information - Breast cancer neoadjuvant - Carboplatin three weekly and paclitaxel weekly
Patient information - Breast cancer neoadjuvant - Carboplatin weekly and paclitaxel weekly
Patient information - Breast cancer neoadjuvant - Docetaxel, pertuzumab and trastuzumab
Patient information - Breast cancer neoadjuvant - Paclitaxel weekly, pertuzumab and trastuzumab three weekly
Patient information - Breast cancer neoadjuvant - TCHP (docetaxel, carboplatin, trastuzumab and pertuzumab)
Patient information - Breast cancer neoadjuvant - Trastuzumab subcutaneous
Patient information - Breast cancer adjuvant - Neratinib
Medical oncology > Breast > Metastatic
Patient information - Advanced, metastatic or recurrent - Olaparib
Patient information - Breast cancer metastatic - Abemaciclib
Patient information - Breast cancer metastatic - AC (doxorubicin and cyclophosphamide)
Patient information - Breast cancer metastatic - Anastrozole
Patient information - Breast cancer metastatic - Capecitabine
Patient information - Breast cancer metastatic - Capecitabine and lapatinib
Patient information - Breast cancer metastatic - Capecitabine and trastuzumab
Patient information - Breast cancer metastatic - Carboplatin
Patient information - Breast cancer metastatic - Carboplatin and gemcitabine
Patient information - Breast cancer metastatic - carboplatin, gemcitabine and pembrolizumab
Patient information - Breast cancer metastatic - CMF (cyclophosphamide, methotrexate, fluorouracil)
Patient information - Breast cancer metastatic - Cyclophosphamide and methotrexate
Patient information - Breast cancer metastatic - Denosumab
Patient information - Breast cancer metastatic - Docetaxel and trastuzumab three weekly
Patient information - Breast cancer metastatic - Docetaxel three weekly
Patient information - Breast cancer metastatic - Docetaxel, pertuzumab and trastuzumab
Patient information - Breast cancer metastatic - Doxorubicin pegylated liposomal
Patient information - Breast cancer metastatic - Doxorubicin three weekly
Patient information - Breast cancer metastatic - Doxorubicin weekly
Patient information - Breast cancer metastatic - EC (epirubicin and cyclophosphamide)
Patient information - Breast cancer metastatic - Eribulin
Patient information - Breast cancer metastatic - Everolimus and exemestane
Patient information - Breast cancer metastatic - Exemestane
Patient information - Breast cancer metastatic - Fulvestrant
Patient information - Breast cancer metastatic - Goserelin
Patient information - Breast cancer metastatic - Letrozole
Patient information - Breast cancer metastatic - nab-Paclitaxel and pembrolizumab
Patient information - Breast cancer metastatic - nab-Paclitaxel weekly
Patient information - Breast cancer metastatic - Paclitaxel and pembrolizumab
Patient information - Breast cancer metastatic - Paclitaxel weekly
Patient information - Breast cancer metastatic - Paclitaxel weekly and trastuzumab three weekly
Patient information - Breast cancer metastatic - Paclitaxel weekly, pertuzumab and trastuzumab three weekly
Patient information - Breast cancer metastatic - Palbociclib
Patient information - Breast cancer metastatic - Ribociclib
Patient information - Breast cancer metastatic - Sacituzumab govitecan
Patient information - Breast cancer metastatic - Tamoxifen
Patient information - Breast cancer metastatic - Trastuzumab deruxtecan
Patient information - Breast cancer metastatic - Trastuzumab emtansine
Patient information - Breast cancer metastatic - Trastuzumab subcutaneous
Patient information - Breast cancer metastatic - Trastuzumab three weekly
Patient information - Breast cancer metastatic - Trastuzumab three weekly and vinorelbine (intravenous)
Patient information - Breast cancer metastatic - Trastuzumab three weekly and vinorelbine (oral)
Patient information - Breast cancer metastatic - Vinorelbine (intravenous)
Patient information - Breast cancer metastatic - Vinorelbine (oral)
Patient information - Breast cancer metastatic - Zoledronic acid
Patient information - Breast cancer metastatic - CMF IV (cyclophosphamide, methotrexate, fluorouracil)
Patient information - Breast cancer metastatic - Gemcitabine and paclitaxel weekly
Patient information - Breast cancer metastatic - nab-Paclitaxel three weekly
Patient information - Breast cancer metastatic - Pamidronate
Medical oncology > Colorectal > Adjuvant and neoadjuvant
Patient information - Adjuvant - CAPOX (XELOX) (capecitabine and oxaliplatin)
Patient information - Bowel cancer adjuvant - Capecitabine
Patient information - Bowel cancer adjuvant - de Gramont modified (fluorouracil and leucovorin)
Patient information - Bowel cancer adjuvant - FOLFOX6 modified (fluorouracil, leucovorin, oxaliplatin)
Patient information - Bowel cancer adjuvant - QUASAR modified (fluorouracil and leucovorin)
Patient information - Bowel cancer adjuvant - Roswell Park modified (fluorouracil and leucovorin)
Patient information - Bowel cancer adjuvant - de Gramont (fluorouracil and leucovorin)
Patient information - Bowel cancer adjuvant - FLOX (fluorouracil, leucovorin, oxaliplatin)
Medical oncology > Colorectal > Anal
Patient information - Anal advanced - Carboplatin and paclitaxel
Patient information - Anal cancer - Cisplatin and fluorouracil with radiation therapy
Patient information - Anal cancer - Mitomycin and capecitabine with radiation therapy
Patient information - Anal cancer - Mitomycin and fluorouracil with radiation therapy
Medical oncology > Colorectal > Metastatic
Patient information - Advanced or metastatic - FOLFIRI modified (fluorouracil, leucovorin, irinotecan)
Patient information - Advanced, metastatic or recurrent - Pembrolizumab
Patient information - Bowel cancer metastatic - Capecitabine
Patient information - Bowel cancer metastatic - Capecitabine and bevacizumab
Patient information - Bowel cancer metastatic - CAPIRI (XELIRI) (capecitabine and irinotecan)
Patient information - Bowel cancer metastatic - CAPIRI (XELIRI) (capecitabine, irinotecan) and bevacizumab
Patient information - Bowel cancer metastatic - CAPOX (XELOX) (capecitabine and oxaliplatin)
Patient information - Bowel cancer metastatic - CAPOX (XELOX) (capecitabine, oxaliplatin) and bevacizumab
Patient information - Bowel cancer metastatic - Cetuximab (two weekly)
Patient information - Bowel cancer metastatic - Cetuximab and encorafenib
Patient information - Bowel cancer metastatic - Cetuximab and irinotecan (two weekly)
Patient information - Bowel cancer metastatic - de Gramont modified (fluorouracil and leucovorin)
Patient information - Bowel cancer metastatic - FOLFIRI modified (fluorouracil, leucovorin, irinotecan) and bevacizumab
Patient information - Bowel cancer metastatic - FOLFIRI modified (fluorouracil, leucovorin, irinotecan) and cetuximab (two weekly)
Patient information - Bowel cancer metastatic - FOLFIRI modified (fluorouracil, leucovorin, irinotecan) and panitumumab
Patient information - Bowel cancer metastatic - FOLFOX 6 modified (fluorouracil, leucovorin, oxaliplatin)
Patient information - Bowel cancer metastatic - FOLFOX6 modified (fluorouracil, leucovorin, oxaliplatin) and bevacizumab
Patient information - Bowel cancer metastatic - FOLFOX6 modified (fluorouracil, leucovorin, oxaliplatin) and cetuximab
Patient information - Bowel cancer metastatic - FOLFOX6 modified (fluorouracil, leucovorin, oxaliplatin) and panitumumab
Patient information - Bowel cancer metastatic - FOLFOXIRI modified (fluorouracil, leucovorin, oxaliplatin, irinotecan)
Patient information - Bowel cancer metastatic - FOLFOXIRI modified (fluorouracil, leucovorin, oxaliplatin, irinotecan) and bevacizumab
Patient information - Bowel cancer metastatic - Irinotecan (three weekly)
Patient information - Bowel cancer metastatic - Panitumumab
Patient information - Bowel cancer metastatic - QUASAR modified (fluorouracil and leucovorin)
Patient information - Bowel cancer metastatic - Raltitrexed
Patient information - Bowel cancer metastatic - Regorafenib
Patient information - Bowel cancer metastatic - Roswell Park modified (fluorouracil and leucovorin)
Patient information - Bowel cancer metastatic - Roswell Park modified (fluorouracil and leucovorin) and bevacizumab
Patient information - Bowel cancer metastatic - TOMOX (raltitrexed and oxaliplatin)
Patient information - Bowel cancer metastatic - Trifluridine/tipiracil
Patient information - Bowel cancer metastatic - Cetuximab
Patient information - Bowel cancer metastatic - Cetuximab (weekly) and irinotecan (two weekly)
Patient information - Bowel cancer metastatic - de Gramont (fluorouracil and leucovorin)
Patient information - Bowel cancer metastatic - FOLFIRI modified (fluorouracil, leucovorin, irinotecan) and cetuximab
Patient information - Bowel cancer metastatic - FOLFOX6 (fluorouracil, leucovorin, oxaliplatin)
Patient information - Bowel cancer metastatic - Irinotecan (weekly)
Medical oncology > Colorectal > Rectal
Patient information - Rectal cancer - Capecitabine with radiation therapy
Patient information - Rectal cancer - Fluorouracil with radiation therapy
Patient information - Rectal cancer adjuvant - CAPOX (XELOX) (capecitabine and oxaliplatin)
Patient information - Rectal cancer adjuvant - FOLFOX 6 modified (fluorouracil, leucovorin, oxaliplatin)
Patient information - Rectal cancer neoadjuvant - CAPOX (XELOX) (capecitabine and oxaliplatin)
Patient information - Rectal cancer neoadjuvant - FOLFIRINOX modified (fluorouracil, leucovorin, irinotecan, oxaliplatin)
Patient information - Rectal cancer neoadjuvant - FOLFOX6 modified (fluorouracil, leucovorin, oxaliplatin)
Medical oncology > Gynaecological > Cervical
Patient information - Cervical cancer locally advanced - Cisplatin with radiation therapy
Patient information - Cervical cancer recurrent or metastatic - Carboplatin and paclitaxel
Patient information - Cervical cancer recurrent or metastatic - Carboplatin, paclitaxel and bevacizumab
Patient information - Cervical cancer recurrent or metastatic - Carboplatin, paclitaxel and pembrolizumab
Patient information - Cervical cancer recurrent or metastatic - Carboplatin, paclitaxel, bevacizumab and pembrolizumab
Patient information - Cervical cancer recurrent or metastatic - Cisplatin, paclitaxel and bevacizumab
Patient information - Cervical cancer recurrent or metastatic - Cisplatin, paclitaxel and pembrolizumab
Patient information - Cervical cancer recurrent or metastatic - Cisplatin, paclitaxel, bevacizumab and pembrolizumab
Medical oncology > Gynaecological > Endometrial
Patient information - Endometrial cancer adjuvant - Carboplatin and paclitaxel
Patient information - Endometrial cancer adjuvant - Carboplatin and paclitaxel following chemoradiation (part 2)
Patient information - Endometrial cancer adjuvant - Cisplatin with radiation therapy
Patient information - Endometrial cancer recurrent - Medroxyprogesterone
Patient information - Endometrial cancer recurrent or metastatic - Carboplatin and paclitaxel
Patient information - Recurrent or metastatic - Lenvatinib and pembrolizumab
Patient information - Soft tissue sarcoma advanced or metastatic - Pazopanib
Patient information - Soft tissue sarcoma locally advanced or metastatic - Doxorubicin
Patient information - Soft tissue sarcoma locally advanced or metastatic - Doxorubicin and ifosfamide
Patient information - Soft tissue sarcoma metastatic - Docetaxel and gemcitabine
Patient information - Endometrial cancer recurrent or metastatic - AP (doxorubicin and cisplatin)
Medical oncology > Gynaecological > Gestational trophoblastic disease
Patient information - Gestational trophoblastic disease high risk - EMA-CO (etoposide, methotrexate, dactinomycin, cyclophosphamide, vincristine)
Patient information - Gestational trophoblastic disease high risk - EP-EMA (etoposide, cisplatin, etoposide, methotrexate, dactinomycin
Patient information - Gestational trophoblastic disease low risk - Dactinomycin
Patient information - Gestational trophoblastic disease low risk - Methotrexate
Patient information - Gestational trophoblastic disease very high risk - EP (etoposide and cisplatin)
Medical oncology > Gynaecological > Ovarian
Patient information - Advanced, metastatic or recurrent - Olaparib
Patient information - Ovarian cancer adjuvant - Carboplatin and paclitaxel
Patient information - Ovarian cancer advanced or metastatic - BEP (bleomycin, etoposide, cisplatin)
Patient information - Ovarian cancer advanced or metastatic - Olaparib and bevacizumab
Patient information - Ovarian, fallopian tube or primary peritoneal cancer advanced - Carboplatin
Patient information - Ovarian, fallopian tube or primary peritoneal cancer advanced - Carboplatin and docetaxel
Patient information - Ovarian, fallopian tube or primary peritoneal cancer advanced - Carboplatin and paclitaxel three weekly
Patient information - Ovarian, fallopian tube or primary peritoneal cancer advanced - Carboplatin and paclitaxel weekly
Patient information - Ovarian, fallopian tube or primary peritoneal cancer advanced - Carboplatin three weekly and paclitaxel weekly
Patient information - Ovarian, fallopian tube or primary peritoneal cancer advanced - Carboplatin, paclitaxel and bevacizumab
Patient information - Ovarian, fallopian tube or primary peritoneal cancer advanced - Cisplatin and paclitaxel (intravenous and intraperitoneal)
Patient information - Ovarian, fallopian tube or primary peritoneal cancer advanced or recurrent - Niraparib
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Carboplatin
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Carboplatin and gemcitabine (day 1 carboplatin)
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Carboplatin and pegylated liposomal doxorubicin
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Carboplatin, gemcitabine and bevacizumab
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Gemcitabine
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Paclitaxel weekly
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Paclitaxel weekly and bevacizumab
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Pegylated liposomal doxorubicin
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Pegylated liposomal doxorubicin and bevacizumab
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Topotecan three weekly
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Topotecan weekly
Patient information - Ovarian, fallopian tube or primary peritoneal cancer recurrent - Topotecan weekly and bevacizumab
Medical oncology > Gynaecological > Vulval
Patient information - Vulval cancer advanced - Cisplatin with radiation therapy
Medical oncology > Head and neck > Definitive chemoradiation
Patient information - Head and neck cancer locally advanced - Carboplatin and fluorouracil with radiation therapy
Patient information - Head and neck cancer locally advanced - Carboplatin with radiation therapy (part 2 of TPF)
Patient information - Head and neck cancer locally advanced - Cisplatin (three weekly) with radiation therapy
Patient information - Head and neck cancer locally advanced - Cisplatin (weekly) with radiation therapy
Patient information - Head and neck cancer locally advanced - Cetuximab with radiation therapy
Medical oncology > Head and neck > Induction chemotherapy
Patient information - Head and neck cancer locally advanced - TPF (docetaxel, cisplatin, fluorouracil)
Medical oncology > Head and neck > Nasopharyngeal
Patient information - Nasopharyngeal cancer locally advanced - Capecitabine metronomic
Patient information - Nasopharyngeal cancer locally advanced - Carboplatin with radiation therapy
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin (three weekly) with radiation therapy
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin (weekly) with radiation therapy
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin and capecitabine (induction)
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin and fluorouracil
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin and gemcitabine (induction)
Patient information - Nasopharyngeal cancer recurrent or metastatic - Cisplatin and gemcitabine
Patient information - Nasopharyngeal cancer recurrent or metastatic - Gemcitabine
Patient information - Nasopharyngeal cancer locally advanced - Carboplatin and fluorouracil
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin (fractionated) with radiation therapy
Medical oncology > Head and neck > Post operative chemoradiation
Patient information - Head and neck cancer locally advanced - Cisplatin (three weekly) with radiation therapy
Patient information - Head and neck cancer locally advanced - Cisplatin (weekly) with radiation therapy
Patient information - Head and neck cancer locally advanced - Carboplatin with radiation therapy
Medical oncology > Head and neck > Recurrent or metastatic
Patient information - Advanced or metastatic - Nivolumab - flat dosing
Patient information - Advanced or metastatic - Nivolumab - weight based dosing
Patient information - Advanced, metastatic or recurrent - Pembrolizumab
Patient information - Head and neck cancer recurrent or metastatic - Carboplatin and fluorouracil
Patient information - Head and neck cancer recurrent or metastatic - Carboplatin and paclitaxel
Patient information - Head and neck cancer recurrent or metastatic - Carboplatin, fluorouracil and cetuximab
Patient information - Head and neck cancer recurrent or metastatic - Carboplatin, fluorouracil and pembrolizumab
Patient information - Head and neck cancer recurrent or metastatic - Carboplatin, paclitaxel and pembrolizumab
Patient information - Head and neck cancer recurrent or metastatic - Cisplatin (three weekly) and fluorouracil
Patient information - Head and neck cancer recurrent or metastatic - Cisplatin and capecitabine
Patient information - Head and neck cancer recurrent or metastatic - Cisplatin, fluorouracil and cetuximab
Patient information - Head and neck cancer recurrent or metastatic - Cisplatin, fluorouracil and pembrolizumab
Patient information - Head and neck cancer recurrent or metastatic - Methotrexate
Patient information - Head and neck cancer recurrent or metastatic - Paclitaxel
Medical oncology > Head and neck > Salivary gland
Patient information - Salivary gland cancer advanced - CAP (cyclophosphamide, doxorubicin, cisplatin)
Patient information - Salivary gland cancer advanced - Cisplatin and vinorelbine
Medical oncology > Head and neck > Thyroid
Patient information - Thyroid cancer locally advanced or metastatic - Lenvatinib
Medical oncology > Neurological > Glioma
Patient information - Brain cancer - Astrocytoma - Temozolomide after radiation therapy
Patient information - Brain cancer - Lomustine and temozolomide with radiation therapy
Patient information - Brain cancer - Oligodendroglioma - PCV (procarbazine, lomustine, vincristine)
Patient information - Brain cancer - Temozolomide after radiation therapy (part 2 of protocol)
Patient information - Brain cancer - Temozolomide after short course radiation therapy (part 2 of protocol)
Patient information - Brain cancer - Temozolomide with radiation therapy (part 1 of protocol)
Patient information - Brain cancer - Temozolomide with short course radiation therapy (part 1 of protocol)
Patient information - Brain cancer high grade or recurrent - Temozolomide
Patient information - Brain cancer low grade - PCV (procarbazine, lomustine, vincristine)
Patient information - Brain cancer recurrent - Bevacizumab
Patient information - Brain cancer recurrent - Lomustine
Patient information - Brain cancer recurrent - Lomustine and bevacizumab
Patient information - Brain cancer high grade recurrent - Carmustine
Patient information - Brain cancer high grade recurrent - PCV (procarbazine, lomustine, vincristine)
Medical oncology > Rare cancers > Colorectal
Patient information - Anal advanced - Carboplatin and paclitaxel
Patient information - Anal cancer - Cisplatin and fluorouracil with radiation therapy
Patient information - Anal cancer - Mitomycin and capecitabine with radiation therapy
Patient information - Anal cancer - Mitomycin and fluorouracil with radiation therapy
Medical oncology > Rare cancers > Gynaecological
Patient information - Vulval cancer advanced - Cisplatin with radiation therapy
Medical oncology > Rare cancers > Head and neck
Patient information - Cisplatin and vinorelbine
Patient information - Nasopharyngeal cancer locally advanced - capecitabine metronomic
Patient information - Nasopharyngeal cancer locally advanced - Carboplatin and fluorouracil
Patient information - Nasopharyngeal cancer locally advanced - Carboplatin with radiation therapy
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin (fractionated) with radiation therapy
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin (three weekly) with radiation therapy
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin (weekly) with radiation therapy
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin and capecitabine (induction)
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin and fluorouracil
Patient information - Nasopharyngeal cancer locally advanced - Cisplatin and gemcitabine (induction)
Patient information - Nasopharyngeal cancer recurrent or metastatic - Cisplatin and gemcitabine
Patient information - Nasopharyngeal cancer recurrent or metastatic - Gemcitabine
Patient information - Salivary gland cancer advanced - CAP (cyclophosphamide, doxorubicin, cisplatin)
Medical oncology > Rare cancers > Melanoma
Patient information - Skin cancer metastatic - Avelumab
Medical oncology > Rare cancers > Neurological
Patient information - Brain cancer - Lomustine and temozolomide with radiation therapy
Patient information - Brain cancer - Temozolomide after radiotherapy (part 2 of protocol)
Patient information - Brain cancer - Temozolomide after short course radiation therapy (part 2 of protocol)
Patient information - Brain cancer - Temozolomide with radiation therapy (part 1 of protocol)
Patient information - Brain cancer - Temozolomide with short course radiation therapy (part 1 of protocol)
Patient information - Brain cancer recurrent - Bevacizumab
Patient information - Brain cancer recurrent - Bevacizumab and lomustine
Patient information - Brain cancer recurrent - Lomustine
Medical oncology > Rare cancers > Respiratory
Patient information - Mesothelioma - Carboplatin and pemetrexed
Patient information - Mesothelioma - Carboplatin, pemetrexed and bevacizumab
Patient information - Mesothelioma - Cisplatin and pemetrexed
Patient information - Mesothelioma - Cisplatin, pemetrexed and bevacizumab
Patient information - Mesothelioma - Ipilimumab and nivolumab - flat dosing
Patient information - Mesothelioma - Ipilimumab and nivolumab - weight based dosing
Patient information - Mesothelioma - Vinorelbine
Medical oncology > Rare cancers > Sarcoma
Patient information - Angiosarcoma locally advanced or metastatic - Paclitaxel
Patient information - Ewing sarcoma - IE (ifosfamide and etoposide)
Patient information - Ewing sarcoma - VAC (vincristine dactinomycin cyclophosphamide)
Patient information - Ewing sarcoma - VAI (vincristine dactinomycin ifosfamide)
Patient information - Ewing sarcoma - VDC (vincristine, doxorubicin, cyclophosphamide)
Patient information - Ewing sarcoma - VIDE (vincristine ifosfamide doxorubicin etoposide)
Patient information - Ewing sarcoma recurrent or metastatic - Irinotecan and temozolomide
Patient information - Ewing sarcoma recurrent or metastatic - TC (topotecan and cyclophosphamide)
Patient information - Giant cell tumour of the bone - Denosumab
Patient information - Liposarcoma advanced or metastatic - Eribulin
Patient information - Osteosarcoma - MAP (methotrexate, doxorubicin, cisplatin)
Medical oncology > Rare cancers > Upper gastrointestinal
Patient information - Gastrointestinal stromal cell tumour (GIST) adjuvant - Imatinib
Patient information - Gastrointestinal stromal cell tumour (GIST) metastatic - Imatinib
Patient information - Gastrointestinal stromal cell tumour (GIST) metastatic - Regorafenib
Patient information - Gastrointestinal stromal cell tumour (GIST) metastatic - Ripretinib
Patient information - Gastrointestinal stromal cell tumour (GIST) metastatic - Sunitinib
Medical oncology > Rare cancers > Urogenital
Patient information - Adrenocortical carcinoma locally advanced or metastatic - Etoposide, doxorubicin, cisplatin and mitotane
Medical oncology > Respiratory > Mesothelioma
Patient information - Mesothelioma - Carboplatin and pemetrexed
Patient information - Mesothelioma - Carboplatin, pemetrexed and bevacizumab
Patient information - Mesothelioma - Cisplatin and pemetrexed
Patient information - Mesothelioma - Cisplatin, pemetrexed and bevacizumab
Patient information - Mesothelioma - Ipilimumab and nivolumab - flat dosing
Patient information - Mesothelioma - Vinorelbine
Patient information - Mesothelioma - Ipilimumab and nivolumab - weight based dosing
Medical oncology > Respiratory > Non small cell lung cancer - Adjuvant/neoadjuvant
Patient information - Lung cancer - Cisplatin and etoposide with radiation therapy superior sulcus (Pancoast)
Patient information - Lung cancer adjuvant - Atezolizumab
Patient information - Lung cancer adjuvant - Cisplatin and pemetrexed
Patient information - Lung cancer adjuvant - Cisplatin and vinorelbine
Patient information - Lung cancer adjuvant - Osimertinib
Patient information - Lung cancer neoadjuvant - Carboplatin, paclitaxel and nivolumab
Patient information - Lung cancer neoadjuvant - Cisplatin, gemcitabine and nivolumab
Patient information - Lung cancer neoadjuvant - Cisplatin, pemetrexed and nivolumab
Medical oncology > Respiratory > Non small cell lung cancer - Advanced/metastatic
Patient information - Advanced or metastatic - Nivolumab - flat dosing
Patient information - Advanced, metastatic or recurrent - Pembrolizumab
Patient information - Locally advanced or metastatic - Cemiplimab
Patient information - Lung cancer advanced - Carboplatin and paclitaxel with radiation therapy
Patient information - Lung cancer advanced or metastatic - Alectinib
Patient information - Lung cancer advanced or metastatic - Carboplatin and pemetrexed
Patient information - Lung cancer advanced or metastatic - Osimertinib
Patient information - Lung cancer advanced or metastatic - Sotorasib
Patient information - Lung cancer locally advanced - Cisplatin and etoposide with radiation therapy
Patient information - Lung cancer locally advanced - Durvalumab - flat dosing
Patient information - Lung cancer locally advanced - Durvalumab - weight based dosing
Patient information - Lung cancer locally advanced or metastatic - Atezolizumab
Patient information - Lung cancer locally advanced or metastatic - Brigatinib
Patient information - Lung cancer locally advanced or metastatic - Carboplatin and docetaxel
Patient information - Lung cancer locally advanced or metastatic - Carboplatin and gemcitabine
Patient information - Lung cancer locally advanced or metastatic - Carboplatin and paclitaxel
Patient information - Lung cancer locally advanced or metastatic - Carboplatin and weekly paclitaxel
Patient information - Lung cancer locally advanced or metastatic - Cisplatin and gemcitabine
Patient information - Lung cancer locally advanced or metastatic - Cisplatin and pemetrexed
Patient information - Lung cancer locally advanced or metastatic - Entrectinib
Patient information - Lung cancer locally advanced or metastatic - Lorlatinib
Patient information - Lung cancer locally advanced or metastatic - Tepotinib
Patient information - Lung cancer metastatic - Afatinib
Patient information - Lung cancer metastatic - Carboplatin, paclitaxel and pembrolizumab
Patient information - Lung cancer metastatic - Carboplatin, paclitaxel, atezolizumab and bevacizumab
Patient information - Lung cancer metastatic - Carboplatin, paclitaxel, ipilimumab and nivolumab
Patient information - Lung cancer metastatic - Carboplatin, pemetrexed and pembrolizumab
Patient information - Lung cancer metastatic - Cisplatin, pemetrexed and pembrolizumab
Patient information - Lung cancer metastatic - Docetaxel
Patient information - Lung cancer metastatic - Gemcitabine
Patient information - Lung cancer metastatic - Pemetrexed
Patient information - Lung cancer metastatic - Vinorelbine (intravenous)
Patient information - Lung cancer metastatic - Vinorelbine (oral)
Patient information - Advanced or metastatic - Nivolumab - weight based dosing
Patient information - Lung cancer advanced or metastatic - Ceritinib
Patient information - Lung cancer locally advanced or metastatic - Carboplatin and vinorelbine
Patient information - Lung cancer locally advanced or metastatic - Cisplatin and vinorelbine
Patient information - Lung cancer metastatic - Crizotinib
Patient information - Lung cancer metastatic - Docetaxel weekly
Patient information - Lung cancer metastatic - Erlotinib
Patient information - Lung cancer metastatic - Gefitinib
Medical oncology > Respiratory > Small cell lung cancer
Patient information - Lung cancer advanced - Topotecan
Patient information - Lung cancer extensive disease - Carboplatin and etoposide
Patient information - Lung cancer extensive disease - Carboplatin and oral etoposide
Patient information - Lung cancer extensive disease - Carboplatin, etoposide and atezolizumab
Patient information - Lung cancer extensive disease - Carboplatin, etoposide and durvalumab
Patient information - Lung cancer extensive disease - CAV (cyclophosphamide, doxorubicin, vincristine)
Patient information - Lung cancer extensive disease - Cisplatin and irinotecan
Patient information - Lung cancer limited disease - Carboplatin and etoposide
Patient information - Lung cancer limited disease - Cisplatin and etoposide
Patient information - Lung cancer limited disease - Cisplatin and etoposide with radiation therapy
Medical oncology > Sarcoma > Bone sarcoma
Patient information - Ewing sarcoma - IE (ifosfamide and etoposide)
Patient information - Ewing sarcoma - VAC (vincristine dactinomycin cyclophosphamide)
Patient information - Ewing sarcoma - VAI (vincristine dactinomycin ifosfamide)
Patient information - Ewing sarcoma - VDC (vincristine, doxorubicin, cyclophosphamide)
Patient information - Ewing sarcoma - VIDE (vincristine ifosfamide doxorubicin etoposide)
Patient information - Ewing sarcoma recurrent or metastatic - Irinotecan and temozolomide
Patient information - Ewing sarcoma recurrent or metastatic - TC (topotecan and cyclophosphamide)
Patient information - Giant cell tumour of the bone - Denosumab
Patient information - Osteosarcoma - MAP (methotrexate, doxorubicin, cisplatin)
Medical oncology > Sarcoma > Soft tissue sarcoma
Patient information - Angiosarcoma locally advanced or metastatic - Paclitaxel
Patient information - Liposarcoma advanced or metastatic - Eribulin
Patient information - Soft tissue sarcoma - Doxorubicin and ifosfamide
Patient information - Soft tissue sarcoma advanced or metastatic - Pazopanib
Patient information - Soft tissue sarcoma advanced or metastatic - trabectedin
Patient information - Soft tissue sarcoma locally advanced or metastatic - Doxorubicin
Patient information - Soft tissue sarcoma metastatic - Docetaxel and gemcitabine
Medical oncology > Skin > Melanoma adjuvant
Patient information - Melanoma adjuvant - Nivolumab - flat dosing
Patient information - Melanoma adjuvant - Dabrafenib and trametinib
Patient information - Melanoma adjuvant - Pembrolizumab
Patient information - Melanoma adjuvant - Nivolumab - weight based dosing
Medical oncology > Skin > Melanoma metastatic
Patient information - Advanced or metastatic - Nivolumab - flat dosing
Patient information - Advanced, metastatic or recurrent - Pembrolizumab
Patient information - Melanoma metastatic - Binimetinib and encorafenib
Patient information - Melanoma metastatic - Cobimetinib and vemurafenib
Patient information - Melanoma metastatic - Dabrafenib and trametinib
Patient information - Melanoma metastatic - Ipilimumab
Patient information - Melanoma metastatic - Ipilimumab and nivolumab
Patient information - Melanoma metastatic - Nivolumab/relatlimab
Patient information - Metastatic - Nivolumab maintenance (flat dosing)
Patient information - Advanced or metastatic - Nivolumab - weight based dosing
Patient information - Melanoma metastatic - Dabrafenib
Patient information - Melanoma metastatic - Dacarbazine
Patient information - Melanoma metastatic - Fotemustine (three weekly)
Patient information - Melanoma metastatic - Fotemustine (weekly)
Patient information - Melanoma metastatic - Temozolomide
Patient information - Melanoma metastatic - Vemurafenib
Patient information - Metastatic - Nivolumab maintenance (weight based dosing)
Medical oncology > Skin > Non-melanoma
Patient information - Advanced, metastatic or recurrent - Pembrolizumab
Patient information - Basal cell carcinoma locally advanced or metastatic - Sonidegib
Patient information - Basal cell carcinoma locally advanced or metastatic - Vismodegib
Patient information - Locally advanced or metastatic - Cemiplimab
Patient information - Skin cancer metastatic - Avelumab
Medical oncology > Upper gastrointestinal > Gastric and oesophageal adjuvant and neoadjuvant
Patient information - Stomach or oesophageal cancer neoadjuvant and adjuvant - Nivolumab
Patient information - Adjuvant - CAPOX (XELOX) (capecitabine and oxaliplatin)
Patient information - Oesophageal cancer definitive - Cisplatin and fluorouracil with radiation therapy
Patient information - Oesophageal cancer definitive - FOLFOX6 modified (fluorouracil, leucovorin, oxaliplatin) with radiation therapy
Patient information - Oesophageal cancer definitive or neoadjuvant - Carboplatin and paclitaxel with radiation therapy
Patient information - Oesophageal cancer neoadjuvant - Cisplatin and fluorouracil with radiation therapy
Patient information - Stomach cancer adjuvant - Cisplatin and capecitabine with radiation therapy
Patient information - Stomach or oesophageal cancer neoadjuvant and adjuvant - FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel)
Medical oncology > Upper gastrointestinal > Gastric and oesophageal metastatic
Patient information - Advanced or metastatic - FOLFIRI modified (fluorouracil, leucovorin, irinotecan)
Patient information - Advanced or metastatic - Nivolumab - flat dosing
Patient information - Metastatic - Trifluridine/tipiracil
Patient information - Oesophageal cancer metastatic - Cisplatin, fluorouracil and nivolumab
Patient information - Stomach or gastroesophageal junction cancer metastatic - Cisplatin, capecitabine and trastuzumab
Patient information - Stomach or gastroesophageal junction cancer metastatic - Cisplatin, fluorouracil and trastuzumab
Patient information - Stomach or gastroesophageal junction cancer metastatic - FOLFOX6 modified (fluorouracil, leucovorin, oxaliplatin) and trastuzumab
Patient information - Stomach or gastroesophageal junction cancer metastatic - Paclitaxel
Patient information - Stomach or gastroesophageal junction cancer metastatic - Paclitaxel and ramucirumab
Patient information - Stomach or oesophageal cancer metastatic - CAPOX (XELOX) (capecitabine and oxaliplatin)
Patient information - Stomach or oesophageal cancer metastatic - CAPOX (XELOX) (capecitabine and oxaliplatin) and nivolumab
Patient information - Stomach or oesophageal cancer metastatic - CAPOX (XELOX) (capecitabine and oxaliplatin) and trastuzumab
Patient information - Stomach or oesophageal cancer metastatic - Cisplatin and capecitabine
Patient information - Stomach or oesophageal cancer metastatic - Cisplatin and fluorouracil
Patient information - Stomach or oesophageal cancer metastatic - Cisplatin, fluorouracil and pembrolizumab
Patient information - Stomach or oesophageal cancer metastatic - Docetaxel
Patient information - Stomach or oesophageal cancer metastatic - FOLFOX6 modified (fluorouracil, leucovorin, oxaliplatin)
Patient information - Stomach or oesophageal cancer metastatic - FOLFOX6 modified (fluorouracil, leucovorin, oxaliplatin) and nivolumab
Patient information - Stomach or oesophageal cancer metastatic - Irinotecan
Patient information - Stomach or oesophageal cancer metastatic - Ramucirumab
Medical oncology > Upper gastrointestinal > Gastrointestinal stromal cell tumours
Patient information - Gastrointestinal stromal cell tumour (GIST) adjuvant - Imatinib
Patient information - Gastrointestinal stromal cell tumour (GIST) metastatic - Imatinib
Patient information - Gastrointestinal stromal cell tumour (GIST) metastatic - Regorafenib
Patient information - Gastrointestinal stromal cell tumour (GIST) metastatic - Ripretinib
Patient information - Gastrointestinal stromal cell tumour (GIST) metastatic - Sunitinib
Medical oncology > Upper gastrointestinal > Hepatic
Patient information - Advanced or metastatic - Nivolumab - flat dosing
Patient information - Advanced or metastatic - Nivolumab - weight based dosing
Patient information - Liver cancer advanced - Sorafenib
Patient information - Liver cancer advanced or metastatic - Atezolizumab and bevacizumab
Patient information - Liver cancer advanced or metastatic - lenvatinib
Medical oncology > Upper gastrointestinal > Neuroendocrine
Patient information - Neuroendocrine cancer advanced - Capecitabine and temozolomide
Patient information - Neuroendocrine cancer advanced - Carboplatin and etoposide
Patient information - Neuroendocrine cancer advanced - Cisplatin and etoposide
Patient information - Neuroendocrine cancer advanced - Lanreotide
Patient information - Neuroendocrine cancer advanced - Octreotide
Patient information - Neuroendocrine cancer advanced - Telotristat ethyl
Patient information - Pancreatic neuroendocrine cancer advanced - Everolimus
Patient information - Pancreatic neuroendocrine cancer advanced - Sunitinib
Medical oncology > Upper gastrointestinal > Pancreas and biliary
Patient information - Advanced or metastatic - FOLFIRI modified (fluorouracil, leucovorin, irinotecan)
Patient information - Biliary cancer adjuvant - Capecitabine
Patient information - Biliary cancer advanced or metastatic - Carboplatin and gemcitabine
Patient information - Biliary cancer advanced or metastatic - Cisplatin and gemcitabine
Patient information - Biliary cancer advanced or metastatic - Cisplatin, gemcitabine and durvalumab
Patient information - Biliary cancer advanced or metastatic - FOLFOX6 modified (fluorouracil, leucovorin, oxaliplatin)
Patient information - Biliary cancer advanced or metastatic - Gemcitabine
Patient information - Biliary cancer advanced or metastatic - Pemigatinib
Patient information - Pancreas cancer adjuvant - Capecitabine and gemcitabine
Patient information - Pancreas cancer adjuvant - FOLFIRINOX modified (fluorouracil, leucovorin, irinotecan, oxaliplatin)
Patient information - Pancreas cancer adjuvant - Gemcitabine
Patient information - Pancreas cancer advanced - Capecitabine with radiation therapy
Patient information - Pancreas cancer advanced - Fluorouracil with radiation therapy
Patient information - Pancreas cancer advanced - Gemcitabine
Patient information - Pancreas cancer metastatic - FOLFIRINOX modified (fluorouracil, leucovorin, irinotecan, oxaliplatin)
Patient information - Pancreas cancer metastatic - Gemcitabine and nab-paclitaxel
Patient information - Pancreas cancer metastatic - Irinotecan nanoliposomal, fluorouracil and leucovorin
Patient information - Pancreas cancer metastatic - OFF (oxaliplatin, fluorouracil, leucovorin)
Patient information - Pancreas cancer neoadjuvant - FOLFIRINOX modified (fluorouracil, leucovorin, irinotecan, oxaliplatin)
Patient information - Pancreas cancer metastatic - FOLFOX6 modified (fluorouracil, leucovorin, oxaliplatin)
Medical oncology > Urogenital > Adrenocortical
Patient information - Adrenocortical carcinoma locally advanced or metastatic - Etoposide, doxorubicin, cisplatin and mitotane
Medical oncology > Urogenital > Bladder and Urothelial
Patient information - Adjuvant - Nivolumab - flat dosing
Patient information - Advanced, metastatic or recurrent - Pembrolizumab
Patient information - Bladder cancer - Intravesical BCG (OncoTICE®)
Patient information - Bladder cancer - Intravesical docetaxel and gemcitabine
Patient information - Bladder cancer - Intravesical gemcitabine
Patient information - Bladder cancer - Intravesical mitomycin
Patient information - Bladder cancer - Intravesical mitomycin single dose post TURBT
Patient information - Bladder/urinary tract cancer - Fluorouracil and mitomycin with radiation therapy
Patient information - Bladder/urinary tract cancer adjuvant - ddMVAC (dose dense methotrexate, vinblastine, doxorubicin, cisplatin)
Patient information - Bladder/urinary tract cancer adjuvant or neoadjuvant - Cisplatin and gemcitabine
Patient information - Bladder/urinary tract cancer locally advanced - Cisplatin with radiation therapy
Patient information - Bladder/urinary tract cancer locally advanced or metastatic - Avelumab
Patient information - Bladder/urinary tract cancer locally advanced or metastatic - Carboplatin and gemcitabine
Patient information - Bladder/urinary tract cancer locally advanced or metastatic - Cisplatin and gemcitabine
Patient information - Bladder/urinary tract cancer locally advanced or metastatic - Enfortumab vedotin
Patient information - Bladder/urinary tract cancer metastatic - MVAC (methotrexate, vinblastine, doxorubicin, cisplatin)
Patient information - Bladder/urinary tract cancer neoadjuvant - ddMVAC (dose dense methotrexate, vinblastine, doxorubicin, cisplatin)
Patient information - Bladder/urinary tract small cell cancer - Carboplatin and etoposide
Patient information - Bladder/urinary tract small cell cancer - Cisplatin and etoposide
Patient information - Urinary tract adjuvant - Carboplatin and gemcitabine
Patient information - Bladder cancer - Intravesical BCG (Connaught strain)
Medical oncology > Urogenital > Prostate
Patient information - Advanced, metastatic or recurrent - Olaparib
Patient information - Prostate cancer - darolutamide
Patient information - Prostate cancer - Enzalutamide
Patient information - Prostate cancer locally advanced or metastatic - Apalutamide
Patient information - Prostate cancer locally advanced or metastatic - Degarelix
Patient information - Prostate cancer metastatic - Bicalutamide
Patient information - Prostate cancer metastatic - Cabazitaxel and prednisolone
Patient information - Prostate cancer metastatic - Denosumab
Patient information - Prostate cancer metastatic - Docetaxel three weekly and prednisolone
Patient information - Prostate cancer metastatic - Docetaxel two weekly and prednisolone
Patient information - Prostate cancer metastatic - Goserelin
Patient information - Prostate cancer metastatic - Leuprorelin (Eligard®)
Patient information - Prostate cancer metastatic - Leuprorelin (Lucrin®)
Patient information - Prostate cancer metastatic - Triptorelin
Patient information - Prostate cancer metastatic - Zoledronic acid
Patient information - Prostate cancer metastatic hormone-resistant - Abiraterone and prednisolone
Patient information - Prostate cancer metastatic hormone-resistant - Abiraterone micronised and methylprednisolone
Patient information - Prostate cancer metastatic hormone-sensitive - Abiraterone and prednisolone
Patient information - Prostate cancer metastatic hormone-sensitive - Abiraterone micronised and methylprednisolone
Patient information - Prostate cancer metastatic hormone-sensitive - Docetaxel
Patient information - Prostate cancer metastatic - Cyproterone
Patient information - Prostate cancer metastatic - Flutamide
Patient information - Prostate cancer metastatic - Mitozantrone and prednisolone
Medical oncology > Urogenital > Renal
Patient information - Advanced or metastatic - Nivolumab - flat dosing
Patient information - Advanced or metastatic - Nivolumab - weight based dosing
Patient information - Kidney cancer advanced or metastatic - Avelumab and axitinib
Patient information - Kidney cancer advanced or metastatic - Axitinib
Patient information - Kidney cancer advanced or metastatic - Cabozantinib
Patient information - Kidney cancer advanced or metastatic - Everolimus
Patient information - Kidney cancer advanced or metastatic - Ipilimumab and nivolumab
Patient information - Kidney cancer advanced or metastatic - Pazopanib
Patient information - Kidney cancer advanced or metastatic - Sorafenib
Patient information - Kidney cancer advanced or metastatic - Sunitinib
Patient information - Kidney cancer advanced or metastatic - Temsirolimus
Patient information - Metastatic - Nivolumab maintenance (flat dosing)
Patient information - Metastatic - Nivolumab maintenance (weight based dosing)
Patient information - Recurrent or metastatic - Lenvatinib and pembrolizumab
Medical oncology > Urogenital > Testicular
Patient information - Testicular cancer adjuvant - BEP (bleomycin, etoposide, cisplatin)
Patient information - Testicular cancer adjuvant - Carboplatin
Patient information - Testicular cancer advanced or metastatic - EP (etoposide, cisplatin)
Patient information - Testicular cancer metastatic - BEP (bleomycin, etoposide, cisplatin)
Patient information - Testicular cancer metastatic - VIP (etoposide, ifosfamide, cisplatin)
Patient information - Testicular cancer recurrent - TIP (paclitaxel, ifosfamide, cisplatin)
Patient information - Testicular cancer recurrent - VeIP (vinblastine, ifosfamide, cisplatin)
Patients and carers > Patient information in other languages > Español (Spanish)
Cambios y cuidado de la piel durante la radioterapia (Skin changes and skin care during radiotherapy - Spanish)
Cómo entender la quimioterapia (Understanding chemotherapy - Spanish)
Entendiendo la inmunoterapia (Understanding immunotherapy – Spanish)
Entendiendo la terapia dirigida (Understanding targeted therapy – Spanish)
La diarrea durante el tratamiento contra el cáncer (Diarrhoea during cancer treatment - Spanish)
Las infecciones durante el tratamiento contra el cáncer (Infection during cancer treatment - Spanish)
Los problemas de la boca durante el tratamiento contra el cáncer (Mouth problems during cancer treatment - Spanish)
Náuseas y vómitos durante el tratamiento contra el cáncer (Nausea and vomiting during cancer treatment - Spanish)
Preguntas comunes de la quimioterapia (Common questions about chemotherapy - Spanish)
Seguridad en la casa con la quimioterapia (Chemotherapy safety at home - Spanish)
Patients and carers > Patient information in other languages > Français (French)
Comprendre l’immunothérapie (Understanding immunotherapy - French)
Comprendre le traitement ciblé (Understanding targeted therapy – French)
Effets secondaires de la radiothérapie sur la peau (Skin changes and skin care during radiotherapy - French)
Nausées et vomissements pendant le traitement anticancéreux (Nausea and vomiting during cancer treatment - French)
Précautions à prendre chez vous pendant la chimiothérapie (Chemotherapy safety at home - French)
Questions fréquemment posées sur la chimiothérapie (Common questions about chemotherapy - French)
Traitement anticancéreux et diarrhée (Diarrhoea during cancer treatment - French)
Traitement anticancéreux et infections (Infection during cancer treatment - French)
Traitement du cancer et problèmes de bouche (Mouth problems during cancer treatment - French)
Patients and carers > Patient information in other languages > Italiano (Italian)
Capire l’immunoterapia (Understanding immunotherapy - Italian)
Capire la chemioterapia (Understanding chemotherapy - Italian)
Capire la terapia a bersaglio molecolare (Understanding targeted therapy – Italian)
Diarrea durante le terapie per il cancro (Diarrhoea during cancer treatment - Italian)
Disturbi alla bocca durante le terapie per il cancro (Mouth problems during cancer treatment - Italian)
Domande comuni in merito alla chemioterapia (Common questions about chemotherapy - Italian)
Infezioni durante le terapie per il cancro (Infection during cancer treatment - Italian )
Mutamenti cutanei e cura della pelle durante la radioterapia (Skin changes and skin care during radiotherapy - Italian)
Nausea e vomito durante le terapie per il cancro (Nausea and vomiting during cancer treatment - Italian)
Precauzioni per la somministrazione sicura della chemioterapia a casa (Chemotherapy safety at home - Italian)
Patients and carers > Patient information in other languages > Tiếng Việt (Vietnamese)
Buồn nôn và bị nôn ói trong khi điều trị ung thư (Nausea and vomiting during cancer treatment - Vietnamese)(
Hiểu biết về về hóa trị (Understanding chemotherapy - Vietnamese)
Nhiễm trùng trong khi điều trị ung thư (Infection during cancer treatment - Vietnamese)
Những câu thường hỏi về hóa trị (Common questions about chemotherapy - Vietnamese)
Những thay đổi ở da và việc chăm sóc da trong thời gian xạ trị (Skin changes and skin care during radiotherapy - Vietnamese)
Những vấn đề ở miệng trong khi điều trị ung thư (Mouth problems during cancer treatment - Vietnamese)
Tiêu chảy trong khi điều trị ung thư (Diarrhoea during cancer treatment - Vietnamese)
Tìm hiểu về trị liệu miễn dịch (Understanding immunotherpay - Vietnamese)
Tìm hiểu về trị liệu nhắm mục tiêu (Understanding targeted therapy – Vietnamese)
Vấn đề an toàn hóa trị khi ở nhà (Chemotherapy safety at home - Vietnamese)
Patients and carers > Patient information in other languages > Ελληνικά (Greek)
Aλλαγές δέρματος και φροντίδα δέρματος κατά τη διάρκεια ακτινοθεραπείας (Skin changes and skin care during radiotherapy - Greek)
Nαυτία και έμετος κατά τη διάρκεια της καρκινικής θεραπείας (Nausea and vomiting during cancer treatment - Greek)
Διάρροια κατά τη διάρκεια της καρκινικής θεραπείας (Diarrhoea during cancer treatment - Greek)
Κατανόηση της ανοσοθεραπείας (Understanding immunotherapy - Greek)
Κατανόηση της στοχευμένης θεραπείας (Understanding targeted therapy – Greek)
Κατανοώντας τη χημειοθεραπεία Πληροφορίες για ασθενείς (Understanding chemotherapy - Greek)
Λοίμωξη κατά τη διάρκεια της καρκινικής θεραπείας (Infection during cancer treatment - Greek)
Παραμείνετε ασφαλής στο σπίτι κατά τη διάρκεια χημειοθεραπείας (Chemotherapy safety at home - Greek)
Στοματικά προβλήματα κατά τη διάρκεια της καρκινικής θεραπείας (Mouth problems during cancer treatment - Greek)
Συνηθισμένες ερωτήσεις σχετικά με τη χημειοθεραπεία (Common questions about chemotherapy - Greek)
Patients and carers > Patient information in other languages > Македонски (Macedonian)
Безбедна хемотерапиjа дома (Chemotherapy safety at home - Macedonian)
Разбирање на имунотерапиjата (Understanding immunotherapy - Macedonian)
Разбирање на насочената терапиjа (Understanding targeted therapy – Macedonian)
Што е хемотерапија? Информации за пациенти (Understanding chemotherapy - Macedonian)
Patients and carers > Patient information in other languages > عربى (Arabic)
فهم العلاج المناعي (Understanding immunotherapy – Arabic)
أسئلة عامّة عن العلاج الكيميائي (Common questions about chemotherapy - Arabic)
الإسهال و العلاج الكيميائي (Diarrhoea during cancer treatment - Arabic)
السالمة في المنزل خالل العالج الكيميائي (Chemotherapy safety at home - Arabic)
العدوى و علاج السرطان (Infection during cancer treatment - Arabic)
الغثيان والتقيؤ عند علاج السرطان (Nausea and vomiting during cancer treatment - Arabic)
تغيّرات الجلد وكيفيّة الإعتناء بالجلد عند العلاج الشّعاعي (Skin changes and skin care during radiotherapy - Arabic)
توضيح العلاج الكيميائي (Understanding chemotherapy - Arabic)
فهم العلاج الموجَّه (Understanding targeted therapy – Arabic)
مشاكل الفم عند علاج السرطان (Mouth problems during cancer treatment - Arabic)
Patients and carers > Patient information in other languages > ไทย (Thai)
เข้าใจการบำบัดแบบกำหนดเป้าหมาย (Understanding targeted therapy – Thai)
เข้าใจการรักษาโดยเคมีบำบัด (Understanding chemotherapy - Thai)
ความปลอดภัยจากเคมีบำบัดที่บ้าน (Chemotherapy safety at home - Thai)
ทำความเข้าใจเกี่ยวกับภูมิคุ้มกันบำบัด (Understanding immunotherapy - Thai)
Patients and carers > Patient information in other languages > 한국어 (Korean)
면역 요법 이해하기 (Understanding immunotherapy – Korean)
방사선 치료 기간 중 피부의 변화와 관리 ( Skin changes and skin care during radiotherapy - Korean)
암 치료 기간 중 발생하는 감염 (Infection during cancer treatment - Korean)
암 치료 기간 중 발생하는 구강 문제 (Mouth problems during cancer treatment - Korean)
암 치료 기간 중 발생하는 메스꺼움과 구토 (Nausea and vomiting during cancer treatment - Korean)
암 치료 기간 중 발생하는 설사 (Diarrhoea during cancer treatment - Korean)
표적 치료 이해하기 (Understanding targeted therapy – Korean)
항암화학요법 이해하기: 환자들을 위한 정보 (Understanding chemotherapy - Korean)
화학요법 치료 기간 중 가정에서 지켜야 할 안전 수칙 (Chemotherapy safety at home - Korean)
화학요법에 관한 흔한 질문들 (Common questions about chemotherapy - Korean)
Patients and carers > Patient information in other languages > 简 (Simplified Chinese)
了解 免疫疗法 (Understanding immunotherapy – Simplified Chinese)
了解 靶向疗法 (Understanding targeted therapy – Simplified Chinese)
什么是化疗 病人须知 (Understanding chemotherapy - Simplified Chinese)
化疗常见问题 (Common questions about chemotherapy - Simplified Chinese)
居家化疗的安全措施 (Chemotherapy safety at home - Simplified Chinese)
放疗期间的肌肤变化与护理 (Skin changes and skin care during radiotherapy - Simplified Chinese)
癌症治疗期间的口腔问题 (Mouth problems during cancer treatment - Simplified Chinese)
癌症治疗期间的恶心和呕吐 (Nausea and vomiting during cancer treatment - Simplified Chinese)
癌症治疗期间的感染 (Infection during cancer treatment - Simplified Chinese)
癌症治疗期间的腹泻 (Diarrhoea during cancer treatment - Simplified Chinese)
Patients and carers > Patient information in other languages > 繁 (Traditional Chinese)
什麼是化療 病人須知 (Understanding chemotherapy - Traditional Chinese)
化療常見問題 (Common questions about chemotherapy - Traditional Chinese)
居家化療的安全措施 (Chemotherapy safety at home - Traditional Chinese)
放射治療期間的肌膚變化與護理 (Skin changes and skin care during radiotherapy - Traditional Chinese)
癌症治療期間的口腔問題 (Mouth problems during cancer treatment - Traditional Chinese)
癌症治療期間的噁心和嘔吐 (Nausea and vomiting during cancer treatment - Traditional Chinese)
癌症治療期間的感染 (Infection during cancer treatment - Traditional Chinese)
癌症治療期間的腹瀉 (Diarrhoea during cancer treatment - Traditional Chinese)
瞭解 免疫療法 (Understanding immunotherapy - Traditional Chinese)
瞭解 靶向療法 (Understanding targeted therapy – Chinese Traditional)
Patients and carers > Patient information sheets > At home
Care at home after an extravasation injury - cold or warm pack
Care at home after an extravasation injury - DMSO and cold pack
Chemotherapy safety at home
Common questions about chemotherapy
Diarrhoea during cancer treatment
Infection during cancer treatment
Managing the side effects of anti-cancer medicines
Nausea and vomiting during cancer treatment
Oral anticancer medicines
Patients and carers > Patient information sheets > Cancer type specifics
Chemotherapy or hormone therapy before breast cancer surgery (neoadjuvant therapy)
Management options for localised prostate cancer
Patients and carers > Patient information sheets > Complementary and alternative medicines
Common questions about chemotherapy
Patients and carers > Patient information sheets > Eating and drinking
Common questions about chemotherapy
Constipation during cancer treatment
Diarrhoea during cancer treatment
Inflammation of the food pipe (oesophagitis) during cancer treatment
Managing the side effects of anti-cancer medicines
Mouth and throat problems during cancer treatment
Nausea and vomiting during cancer treatment
Patients and carers > Patient information sheets > Fertility, sex, pregnancy and breastfeeding
Androgen deprivation therapy (ADT) for prostate cancer
Cancer treatment and fertility for people who were assigned female at birth
Cancer treatment and fertility for people who were assigned male at birth
Common questions about chemotherapy
Managing the side effects of anti-cancer medicines
Vaginal changes after radiation therapy to the pelvis
Patients and carers > Patient information sheets > How you have anticancer medicine treatment
Intrathecal treatment
Oral anti-cancer medicines
Treatment through a CADD
®
-Solis VIP pump
Treatment through a CADD-Legacy
®
1 pump
Treatment through a CADD-Legacy
®
Plus pump
Treatment through a peripherally inserted central catheter (PICC)
Treatment through a portacath (totally implantable venous access device TIVAD)
Treatment through a tunnelled cuffed - centrally inserted central catheter (tc-CICC)
Treatment through an elastomeric infusor
Treatment through an intraventricular reservoir
Patients and carers > Patient information sheets > How you have radiation therapy treatment
Care at home after an extravasation injury - cold or warm pack
Immobilisation masks for radiation therapy simulation and treatment
IV contrast during radiation therapy simulation scans
Preparing your bladder and bowel for pelvic radiation therapy
Understanding total body irradiation (TBI) - Multi-fraction treatment
Understanding total body irradiation (TBI) - Single fraction treatment
Patients and carers > Patient information sheets > Managing side effects
Androgen deprivation therapy (ADT) for prostate cancer
Bladder irritation (cystitis) during cancer treatment
Changes to taste or smell during cancer treatment
Common questions about chemotherapy
Constipation during cancer treatment
Diarrhoea during cancer treatment
Feeling tired (fatigue) during cancer treatment
Hair loss during cancer treatment
Infection during cancer treatment
Inflammation of the food pipe (oesophagitis) during cancer treatment
Lung damage from bleomycin
Lymphoedema and radiation therapy
Managing the side effects of anti-cancer medicines
Memory changes and chemotherapy (chemo brain)
Mouth and throat problems during cancer treatment
Nausea and vomiting during cancer treatment
Peripheral neuropathy during cancer treatment
Skin changes and skin care during radiation therapy
Understanding total body irradiation (TBI) - Multi-fraction treatment
Understanding total body irradiation (TBI) - Single fraction treatment
Vaginal changes after radiation therapy to the pelvis
Patients and carers > Patient information sheets > Treating cancer with medicines
Androgen deprivation therapy (ADT) for prostate cancer
Anti-cancer therapy before breast cancer surgery (neoadjuvant therapy)
Common questions about chemotherapy
Management options for localised prostate cancer
Oral anticancer medicines
Understanding chemotherapy
Understanding immunotherapy
Understanding targeted therapy
Patients and carers > Patient information sheets > Treating cancer with radiation therapy
Lymphoedema and radiation therapy
Preparing your bladder and bowel for pelvic radiation therapy
Understanding radiation therapy
Understanding radiation therapy simulation (radiation planning)
Understanding total body irradiation (TBI) - Multi-fraction treatment
Understanding total body irradiation (TBI) - Single fraction treatment
Patients and carers > Patient information sheets > Vaccinations
Common questions about chemotherapy
Infection during cancer treatment
Patients and carers > Patient information sheets > Your family and friends
Chemotherapy safety at home
Common questions about chemotherapy
Infection during cancer treatment
Informing family members about hereditary cancer
Memory changes and chemotherapy (chemo brain)
Patients and carers > Patient information videos
Feeling tired (fatigue) during cancer treatment
Hair loss during chemotherapy
Infection during cancer treatment
Introduction to chemotherapy
Introduction to radiation therapy
Mouth problems during cancer treatment
Nausea and vomiting during cancer treatment
Radiation oncology > Breast
Patient information - Breast cancer adjuvant - ductal carcinoma in situ (DCIS) external beam radiation therapy (EBRT)
Patient information - Breast cancer adjuvant - nodal irradiation external beam radiation therapy (EBRT)
Patient information - Breast cancer adjuvant - partial breast external beam radiation therapy (EBRT)
Patient information - Breast cancer adjuvant - post-mastectomy (chest wall) external beam radiation therapy (EBRT)
Patient information - Breast cancer adjuvant - whole breast external beam radiation therapy (EBRT)
Patient information - Breast cancer adjuvant/neoadjuvant - inflammatory breast cancer external beam radiation therapy (EBRT)
Radiation oncology > Colorectal
Patient information - Anal cancer - External Beam Radiation Therapy
Patient information - Rectal cancer - External Beam Radiation Therapy (EBRT) - post-operative
Patient information - Rectal cancer - External Beam Radiation Therapy (EBRT) - pre-operative long-course
Patient information - Rectal cancer - External Beam Radiation Therapy (EBRT) - pre-operative short-course
Radiation oncology > Gynaecological
Patient information - Cervical cancer - brachytherapy boost
Patient information - Cervical cancer - external beam radiation therapy (EBRT)
Patient information - Cervical cancer - post-operative adjuvant external beam radiation therapy (EBRT) with chemotherapy
Patient information - Cervical cancer - post-operative external beam radiation therapy (EBRT)
Patient information - Endometrial cancer - brachytherapy
Patient information - Endometrial cancer - external beam radiation therapy (EBRT)
Patient information - Endometrial cancer - post-operative adjuvant external beam radiation therapy (EBRT)
Patient information - Endometrial cancer - post-operative adjuvant vaginal brachytherapy
Patient information - Vulva cancer - external beam radiation therapy (EBRT)
Patient information - Vulva cancer - post-operative adjuvant external beam radiation therapy (EBRT)
Radiation oncology > Haematology
Patient information - Hodgkin lymphoma - advanced-stage - External Beam Radiation Therapy (EBRT)
Patient information - Hodgkin lymphoma - early stage - External Beam Radiation Therapy (EBRT)
Patient information - Non-Hodgkin lymphoma (NHL) - diffuse large B-cell - advanced stage - External Beam Radiation Therapy (EBRT)
Patient information - Non-Hodgkin lymphoma (NHL) - diffuse large B-cell - limited stage - External Beam Radiation Therapy (EBRT)
Patient information - Non-Hodgkin lymphoma (NHL) - follicular - External Beam Radiation Therapy (EBRT)
Patient information - Primary CNS lymphoma - Whole brain external beam radiation therapy (EBRT)
Radiation oncology > Head and neck
Patient information - External Beam Radiation Therapy (EBRT) - with chemotherapy
Patient information - Head and neck cancer post operative - External Beam Radiation Therapy (EBRT)
Patient information - Larynx cancer - External Beam Radiation Therapy (EBRT)
Patient information - Larynx or hypopharynx cancer - External Beam Radiation Therapy (EBRT) - with chemotherapy
Patient information - Nasopharynx cancer - External Beam Radiation Therapy (EBRT)
Patient information - Nasopharynx cancer - External Beam Radiation Therapy (EBRT) - with chemotherapy
Patient information - Oral cavity - External Beam Radiation Therapy (EBRT)
Patient information - Oropharynx cancer - External Beam Radiation Therapy (EBRT)
Patient information - Oropharynx cancer - External Beam Radiation Therapy (EBRT) - with chemotherapy
Patient information - Paranasal sinus and nasal cavity cancer - External Beam Radiation Therapy (EBRT) - post-operative
Patient information - Salivary gland cancer - External Beam Radiation Therapy (EBRT) - post-operative
Radiation oncology > Neurological
Patient information - Brain cancer - External beam radiation therapy - glioblastoma (short-course)
Patient information - Brain cancer - External Beam Radiation Therapy (EBRT) - high grade glioma
Patient information - Brain cancer - External Beam Radiation Therapy (EBRT) - low-grade glioma
Patient information - Brain cancer - External beam radiation therapy and chemotherapy - glioblastoma (long-course)
Patient information - Brain metastases - post-operative stereotactic radiation therapy
Patient information - Brain metastases - stereotactic radiation therapy
Patient information - Brain metastases - whole brain (hippocampal avoidance) external beam radiation therapy (EBRT)
Patient information - Brain metastases - whole brain external beam radiation therapy (EBRT)
Radiation oncology > Palliative
Patient information - Bladder cancer - External Beam Radiation Therapy (EBRT) - palliative
Patient information - Bone metastases - External Beam Radiation Therapy (EBRT)
Patient information - Bone metastases - Non-spinal bone - Stereotactic ablative radiation therapy (SABR)
Patient information - Bone metastases - Spinal bone - Stereotactic ablative radiation therapy (SABR)
Patient information - Brain metastases - post-operative stereotactic radiation therapy
Patient information - Brain metastases - stereotactic radiation therapy
Patient information - Brain metastases - whole brain (hippocampal avoidance) external beam radiation therapy (EBRT)
Patient information - Brain metastases - whole brain external beam radiation therapy (EBRT)
Patient information - Liver cancer advanced - External Beam Radiation Therapy (EBRT)
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - palliative
Patient information - Metastatic - Liver - Stereotactic ablative radiation therapy (SABR)
Patient information - Metastatic - Lung oligometastases - Stereotactic ablative radiation therapy (SABR)
Patient information - Spinal cord compression - External Beam Radiation Therapy (EBRT)
Patient information - Superior vena cava obstruction (SVCO) - External Beam Radiation Therapy (EBRT)
Radiation oncology > Respiratory
Patient information - Brain irradiation for small cell lung cancer - External Beam Radiation Therapy (EBRT) - extensive stage
Patient information - Brain irradiation for small cell lung cancer - External Beam Radiation Therapy (EBRT) - limited stage
Patient information - Lung cancer - External beam radiation therapy - non-small cell lung cancer (hypofractionation)
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - non small cell lung cancer (NSCLC)
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - palliative
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - post operative
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - small cell lung cancer (SCLC)
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - superior sulcus/Pancoast
Patient information - Lung cancer - Non small cell (central) - Stereotactic ablative radiation therapy (SABR)
Patient information - Lung cancer - Non small cell (peripheral) - Stereotactic ablative radiation therapy (SABR)
Patient information - Lung cancer - Small cell lung cancer (SCLC) - External Beam Radiation Therapy (EBRT)
Patient information - Lung oligometastases - Stereotactic ablative radiation therapy (SABR)
Patient information - Superior vena cava obstruction (SVCO) - External Beam Radiation Therapy (EBRT)
Radiation oncology > Skin
Patient information - Skin cancer - External Beam Radiation Therapy (EBRT) - basal cell carcinoma (BCC)
Patient information - Skin cancer - External Beam Radiation Therapy (EBRT) - melanoma post -operative
Patient information - Skin cancer - External Beam Radiation Therapy (EBRT) - Merkel cell carcinoma (MCC)
Patient information - Skin cancer - External Beam Radiation Therapy (EBRT) - post-operative Merkel cell carcinoma (MCC)
Patient information - Skin cancer - External Beam Radiation Therapy (EBRT) - post-operative squamous cell carcinoma (SCC)
Patient information - Skin cancer - External Beam Radiation Therapy (EBRT) - squamous cell carcinoma (SCC)
Radiation oncology > Stereotactic
Patient information - Bone metastases - Non-spinal bone - Stereotactic ablative radiation therapy (SABR)
Patient information - Bone metastases - Spinal bone - Stereotactic ablative radiation therapy (SABR)
Patient information - Brain metastases - stereotactic radiation therapy
Patient information - Brain metastases - post-operative stereotactic radiation therapy
Patient information - Liver cancer - Stereotactic ablative radiation therapy (SABR)
Patient information - Lung cancer - Non small cell (central) - Stereotactic ablative radiation therapy (SABR)
Patient information - Lung cancer - Non small cell (peripheral) - Stereotactic ablative radiation therapy (SABR)
Patient information - Lung oligometastases - Stereotactic ablative radiation therapy (SABR)
Patient information - Metastatic - Liver - Stereotactic ablative radiation therapy (SABR)
Patient information - Prostate cancer - Stereotactic ablative radiation therapy (SABR)
Radiation oncology > Upper gastrointestinal
Patient information - Liver cancer - Stereotactic ablative radiation therapy (SABR)
Patient information - Metastatic - Liver - Stereotactic ablative radiation therapy (SABR)
Patient information - Oesophageal cancer definitive - External Beam Radiation Therapy
Patient information - Oesophageal cancer definitive - External beam radiation therapy - Pre-operative
Patient information - Pancreas cancer - External Beam Radiation Therapy (EBRT)
Patient information - Stomach cancer adjuvant - External Beam Radiation Therapy (EBRT)
Radiation oncology > Urogenital > Bladder
Patient information - Bladder cancer - External Beam Radiation Therapy (EBRT)
Patient information - Bladder cancer - External Beam Radiation Therapy (EBRT) - palliative
Radiation oncology > Urogenital > Prostate
Patient information - Prostate cancer - Stereotactic ablative radiation therapy (SABR)
Patient information - Prostate cancer - Brachytherapy radiation treatment (HDR)
Patient information - Prostate cancer - Brachytherapy radiation treatment (LDR seeds)
Patient information - Prostate cancer - External beam radiation therapy - definitive - prostate and lymph nodes
Patient information - Prostate cancer - External beam radiation therapy - definitive (high)
Patient information - Prostate cancer - External beam radiation therapy - definitive (intermediate)
Patient information - Prostate cancer - External beam radiation therapy - definitive (low)
Patient information - Prostate cancer - External beam radiation therapy (hypofractionated)
Patient information - Prostate cancer - External beam radiation therapy after surgery (adjuvant)
Patient information - Prostate cancer - External beam radiation therapy after surgery (salvage)
Patient information - Prostate cancer metastatic - External beam radiation therapy
Title
Content